Form 4 for GALT GALECTIN THERAPEUTICS INC
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001133416-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-01-06 | 2026-01-02 | GALT | LEWIS JOEL | Pres, CEO, Dir | M - OptEx | $0.00 | +84.0K | 916.6K | +10% | $0 |
| DMT | 2026-01-06 | 2026-01-02+ | GALT | LEWIS JOEL | Pres, CEO, Dir | S - Sale+OE | $3.83 | -84.0K | 870.3K | -9% | -$321.4K |
| DT | 2026-01-06 | 2026-01-02 | GALT | LEWIS JOEL | Pres, CEO, Dir | M - OptEx | $0.00 | -84.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | M | A | 84,000 | $0.00 | 916,592 | D | — | — | (F2) Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. |
| 2 | Common | Common Stock | 2026-01-06 | S | D | 37,698 | $3.58 | 832,592 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. (F7) The shares were sold in multiple transactions at prices ranging from $3.36 to $3.79. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 3 | Common | Common Stock | 2026-01-02 | S | D | 18,571 | $4.20 | 898,021 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. (F4) The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 4 | Common | Common Stock | 2026-01-05 | S | D | 27,731 | $3.91 | 870,290 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. (F6) The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 5 | Derivative | Restricted Stock Unit | 2026-01-02 | M | D | 84,000 | $0.00 | 0 | D | $0.00 · 2026-01-01 to — | 84,000 Common Stock | (F5) Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. (F2) Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. |